Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
4
×
biotech
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
eli lilly
4
×
indiana blog main
indiana top stories
life sciences
merck
4
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
4
×
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
clinical trials
deals
moderna
astrazeneca
boehringer ingelheim
bristol-myers squibb
cancer immunotherapy
What
bio
roundup
companies
drug
debut
moves
nash
news
week
acquisitions
approval
approved
biggest
biogen’s
biopharmaceutical
black
build
buy
ceo
company’s
continue
convo
daniel
diamond
diamond’s
digital
disease
dyne’s
earlier
epidemic
failures
fatty
fda
frenzied
gilead
growing
indication
known
leading
led
Language
unset
Current search:
abbvie
×
biotech
×
" eli lilly "
×
" texas blog main "
×
merck
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More